Nabajyoti Goswami

Nabajyoti Goswami

Auto-generated profile, based on publicly available information

Nabajyoti Goswami

National Institute of Electronics and Information Technology, Guwahati, 781008, Assam, India

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2020 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
SMSaurov Mahanta
Saurov Mahanta
PCPurvita Chowdhury
Purvita Chowdhury
NGNeelutpal Gogoi
Neelutpal Gogoi
NGNabajyoti Goswami
Nabajyoti Goswami
DBDebajit Borah
Debajit Borah
BGBhaskarjyoti Gogoi
Bhaskarjyoti Gogoi
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) which was first reported in Wuhan province of China, has become a deadly pandemic causing alarmingly high morbidity and mortality. In the absence of new targeted drugs and vaccines against SARS-CoV-2 at present, the choices for effective treatments are limited. Therefore, considering the exigency of the situation, we focused on identifying the available approved drugs as potential inhibitor against the promising Coronavirus drug target, the Main Protease, using computer-aided methods. We created a library of U. S. Food and Drug Administration approved anti-microbial drugs and virtually screened it against the available crystal structures of Main Protease of the virus. The study revealed that Viomycin showed the highest -CDocker energy after docking at the active site of SARS-CoV-2 Main Protease. It is noteworthy that Viomycin showed higher -CDocker energy as compared to the drugs currently under clinical trial for SARS-CoV-2 treatment viz. Ritonavir and Lopinavir. Additionally, Viomycin formed higher number of H-bonds with SARS-CoV-2 Main Protease than its co-crystallised inhibitor compound N3. Molecular dynamics simulation further showed that Viomycin embedded deeply inside the binding pocket and formed robust binding with SARS-CoV-2 Main Protease. Therefore, we propose that Viomycin may act as a potential inhibitor of the Main Protease of SARS-CoV-2. Further optimisations with the drug may support the much-needed rapid response to mitigate the pandemic. Communicated by Ramaswamy H. Sarma

19 July 2012 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
SBSarath Kumar Baskaran
Sarath Kumar Baskaran
NGNabajyoti Goswami
Nabajyoti Goswami
SSSudhagar Selvaraj
Sudhagar Selvaraj
VMVelusamy Shanmuganathan Muthusamy
Velusamy Shanmuganathan Muthusamy
BLBaddireddi Subhadra Lakshmi
Baddireddi Subhadra Lakshmi

1 March 2009 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
KSKrishnan Subramanian
Krishnan Subramanian
CSChinnasamy Selvakkumar
Chinnasamy Selvakkumar
KVKontham Sanathkumar Vinaykumar
Kontham Sanathkumar Vinaykumar
NGNabajyoti Goswami
Nabajyoti Goswami
SMSankaranarayanan Meenakshisundaram
Sankaranarayanan Meenakshisundaram
BLBaddireddi Subhadra Lakshmi
Baddireddi Subhadra Lakshmi

28 November 2022 in ACS Omega
Verified
Journal Article
Open access
SBSiddhartha A. Barua
Siddhartha A. Barua
NGNabajyoti Goswami
Nabajyoti Goswami
NMNeha Mishra
Neha Mishra
USUlka U. Sawant
Ulka U. Sawant
AVAshok K. Varma
Ashok K. Varma
BRCA1 and BARD1 are important proteins in the homologous DNA damage repair pathways. Different genetic variants identified in these proteins have been clinically correlated with the occurrence of hereditary breast and ovarian cancer (HBOC). Variants of unknown significance (VUS) reported in the BRCT domains of BRCA1 and BARD1 substantiate the importance of BRCT domain-containing proteins for genomic integrity. To classify the pathogenicity of variants, in silico, structural and molecular dynamics (MD)-based approaches were explored. Different variants reported in the BRCT region were retrieved from cBioPortal, LOVD3, BRCA Exchange, and COSMIC databases to evaluate the pathogenicity. Multiple sequence alignment and superimposition of the structures of BRCA1 BRCT and BARD1 BRCT domains were performed to compare alterations in folding patterns. From 11 in silico predictions servers, variants reported to be pathogenic by 70% of the servers were considered for structural analysis. To our observations, four residue pairs of both the proteins were reported, harboring 11 variants, H1686Y, W1718L, P1749L, P1749S, and W1837L variants for BRCA1 BRCT and H606D, H606N, W635L, P657L, P657S, and W762F for BARD1 BRCT. MD simulations of the BRCT repeat regions of these variants and wild-type proteins were performed to evaluate the differences of folding patterns. Root mean square deviation (RMSD), R g, solvent-accessible surface area (SASA), and root mean square fluctuation (RMSF) of variants showed slight differences in the folding patterns from the wild-type proteins. Furthermore, principal components analysis of H1686Y, P1749S, and W1718L variants of BRCA1 showed less flexibility than the wild type, whereas that of H606D, W635L, and W762F of BARD1 showed more flexibility than the wild type. Normal mode analysis of the energy minima from the simulation trajectories revealed that most of the variants do not show much differences in the flexibility compared to the wild-type proteins, except for the discrete regions in the BRCT repeats, most prominently in the 1798-1801 amino acid region of BRCA1 and at the residue 744 in BARD1.

11 June 2017 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
NGNabajyoti Goswami
Nabajyoti Goswami
IHIftikar Hussain
Iftikar Hussain
PBProbodh Borah
Probodh Borah
PagN is a highly immunogenic 27-kDa outer membrane adhesin present in Salmonella Typhi. It plays a major role in the pathogenesis of typhoid fever and has emerged as a strong vaccine candidate. In this report, we predict the three-dimensional structure of PagN and describe the conformational dynamics associated with its four extracellular loops based on two 100-ns molecular dynamics simulations at 300 and 310 K. The formation and deformation of the secondary structures on these loops were also investigated during the simulations which revealed loops L1 and L2 to be highly flexible, whereas the relative flexibility of loops L3 and L4 was minimal. Essential dynamics and principal component analysis deciphered more realistic dynamic behaviours of the loops, particularly at 310 K. Moreover, our epitope predictions suggest that the antigenic peptides for B-cell recognition are located within the loops L1 and L2, while those for T-cell recognition are located within the loops L3 and L4. The binding specificities of the antigenic peptides towards specific human MHC-I and MHC-II HLA alleles closely resembled the stability of the loops L3 and L4 inferred from the simulations. Finally, we identified potential antigenic peptides in the flexible (L1 and L2) as well as stable (L3 and L4) regions of PagN for both B- and T-cell recognitions, which can help in developing effective sub-unit vaccines.

4 February 2022 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
RBRene Barbie Browne
Rene Barbie Browne
NGNabajyoti Goswami
Nabajyoti Goswami
PBProbodh Borah
Probodh Borah
JRJayanti Datta Roy
Jayanti Datta Roy
Prostate cancer is the World’s second most common cancer, with the fifth-highest male mortality rate. Point mutations such as T877A and W741L are frequently seen in advanced prostate cancer patients, conferring drug-resistance and hence driving cancer growth. Such occurrence of drug resistance in prostate cancer necessitates designing of suitable ligands to ensure better interactions with the receptors which can block the progression of the disease. The present study focus on the modification of plant-derived flavonoids that might act as inhibitors against such point mutations namely, T877A and W741L. In T877A mutation threonine is substituted by alanine at the 877 codon and W741L mutation, tryptophan is substituted by lysine at the 741 codon in prostate cancer. The study revolved on the aspect of the evaluation of Isobavachin and its derivatives as a potential agent to tackle such point mutations by using the in silico approach. A total of 98 molecular dockings were performed to find the ligand-receptor complexes with the lowest binding energy employing Autodock Software to conduct the blind and site-specific docking. Additionally, ligands were screened for Drug-likeness and toxicity using several tools yielding eight possible drug candidates. Based on the results of Molecular Docking, Drug-likeness, and ADMET testing, ten structures, including six complexes and three receptors were subjected to molecular dynamics simulation of 100 ns covering RMSD, RMSF, Rg, and MM/PBSA. Based on the simulation results, Isobavachin, IsoMod4, and IsoMod7 were concluded to be stable and exhibited potential properties for developing a novel drug to combat prostate cancer and its associated drug-resistance. Graphical Abstract Communicated by Ramaswamy H. Sarma